SGI-110 could enter PH3 as soon as 4Q13. That they may partner by territory and retain some piece.
At13387 Gives combination drug a double hit. Att13387 goes after key resistance areas that approved drugs miss. Key here Breast and prostrate act similar.
HVC IND in the first half of 2013.
The landscape cluttered the questions on at13387. Apparently in Prostrate the make or break is out there on several trials. The key for us is if at13387 heads off pathways cancer takes. Our presentor, who has 4 key drugs he was instrumental, had a positive bias towards at13387. He gave his personal insights into why he favors at13387/Abitaterone. The key here 13387 hits multiple targets.
There was a lot of stuff covered. I believe the news is very good for astx. The resistance to current drugs, is something I believe astx with sgi-110 and at13387 is addressing. That was clear from these professors. At least two INDs next year and 6 updates at AACR on 6 drugs. The second ph2 on sgi-110 now moved to 1Q13.
What makes sgi-110 a benefit in solid tumors, it's ability to hit demethylation even in small does, over a long period, with lower side effects.
Lots of Talk, Talk, Talk adds up to nothing.
4Q becomes 1Q 2014 or 2Q 2014 or reformulation or some other issue.
Thus far they have guesses, talking points, and not much else.
Got a lot of ground to cover before anything real is on the horizon.
Unless and Until!
It's boring. But there are points to understand and appreciate. Buckland states something very fast. I suggest you play that a few times. I didn't catch everything as I would like. As investors go, this was no eye opener. They concentrate on the science. There were numerous questions to professors that clouded our science.